Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Surgery

Metabolic surgery: the cutting edge of diabetes care

Nature Reviews Gastroenterology & Hepatology volume 14, pages 389–390 (2017)Cite this article

Subjects

International guidelines recognize surgery as a standard treatment option for type 2 diabetes mellitus, including in mildly obese individuals who fail to respond to conventional therapies. A new report from the STAMPEDE trial now provides further evidence and emphasizes the need for health care regulators to introduce appropriate reimbursement policies for metabolic surgery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The 2nd Diabetes Surgery Summit (DSS-II) algorithm for patient selection for surgical treatment of type 2 diabetes mellitus.

References

  1. Rubino, F. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes. a joint statement by International Diabetes Organizations. Diabetes Care 39, 861–877 (2016).

    Article  CAS  Google Scholar 

  2. Batterham, R. L. & Cummings, D. E. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 39, 893–901 (2016).

    Article  Google Scholar 

  3. Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. N. Engl. J. Med. 376, 641–651 (2017).

    Article  Google Scholar 

  4. Mingrone, G. et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386, 964–973 (2015).

    Article  Google Scholar 

  5. Zinman, B. et al. Cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  Google Scholar 

  6. Sjostrom, L. Review of the key results from the Swedish Obese Subjects (SOS) trial — a prospective controlled intervention study of bariatric surgery. J. Intern. Med. 273, 219–234 (2013).

    Article  CAS  Google Scholar 

  7. Rubino, F. & Marescaux, J. The effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann. Surg. 239, 1–11 (2004).

    Article  Google Scholar 

  8. Rubino, F. Medical research: time to think differently about diabetes. Nature 533, 459–461 (2016).

    Article  CAS  Google Scholar 

  9. Panunzi, S., De Gaetano, A., Carnicelli, A. & Mingrone, G. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann. Surg. 261, 459–467 (2015).

    Article  Google Scholar 

  10. Cummings, D. E. & Cohen, R. V. Bariatric/metabolic surgery to treat type 2 diabetes in patients with a BMI <35 kg/m2. Diabetes Care 39, 924–933 (2016).

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Anna Kesmiri for her help with the original illustration of this article.

Author information

Authors and Affiliations

  1. Department of Metabolic and Bariatric Surgery, Diabetes and Nutrition Science Division, King's College London, Denmark Hill Campus, 10 Cutcombe Road, London, SE5 9RJ, UK

    Francesco Rubino & Spyros Panagiotopoulos

Authors
  1. Francesco Rubino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Spyros Panagiotopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Rubino.

Ethics declarations

Competing interests

F.R. serves as scientific advisory board member for Fractyl and has received consulting honoraria from Ethicon Endosurgery.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rubino, F., Panagiotopoulos, S. Metabolic surgery: the cutting edge of diabetes care. Nat Rev Gastroenterol Hepatol 14, 389–390 (2017). https://doi.org/10.1038/nrgastro.2017.45

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.45

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing